Omalizumab for the Treatment of Chronic Idiopathic or Spontaneous Urticaria
- 7 March 2013
- journal article
- research article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 368 (10), 924-935
- https://doi.org/10.1056/nejmoa1215372
Abstract
Many patients with chronic idiopathic urticaria (also called chronic spontaneous urticaria) do not have a response to therapy with H1-antihistamines, even at high doses. In phase 2 trials, omalizumab, an anti-IgE monoclonal antibody that targets IgE and affects mast-cell and basophil function, has shown efficacy in such patients.Keywords
This publication has 26 references indexed in Scilit:
- Adaptation and validation of the Urticaria Patient Daily Diary for adolescentsAllergy and Asthma Proceedings, 2012
- A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine–refractory chronic idiopathic urticariaJournal of Allergy and Clinical Immunology, 2011
- Effects of omalizumab on basophil and mast cell responses using an intranasal cat allergen challengeJournal of Allergy and Clinical Immunology, 2010
- EAACI/GA2LEN/EDF/WAO guideline: definition, classification and diagnosis of urticariaAllergy, 2009
- The Impact of Chronic Idiopathic Urticaria on Quality of Life in Korean PatientsAnnals of Dermatology, 2009
- New concepts in chronic urticariaCurrent Opinion in Immunology, 2008
- Effect of Anti-IgE (Omalizumab) in Chronic Idiopathic Urticaria (CIU) PatientsJournal of Allergy and Clinical Immunology, 2008
- Etoricoxib challenge in patients with chronic urticaria with NSAID intoleranceClinical and Experimental Dermatology, 2007
- Anti-IgE (omalizumab) inhibits late-phase reactions and inflammatory cells after repeat skin allergen challengeJournal of Allergy and Clinical Immunology, 2005
- Omalizumab-induced reductions in mast cell FcεRI expression and functionJournal of Allergy and Clinical Immunology, 2004